SCHEMBL16708142

SCHEMBL16708142

Cc1cc2oc(C(=O)CBr)cc2cc1Br

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 2/20 0.38
CSNK2A2 P19784 1/20 0.38
CSNK2B P67870 1/20 0.38
CSNK2A1 P68400 1/20 0.38
CSNK2A3 Q8NEV1 1/20 0.38
GSK3B P49841 2/20 0.37
NPC1 O15118 5/20 0.35
RAB9A P51151 4/20 0.35
STING1 Q86WV6 1/20 0.35
LMNA P02545 3/20 0.34
ALDH1A1 P00352 3/20 0.34
HPGD P15428 3/20 0.34
KDM4E B2RXH2 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
GLA P06280 1/20 0.34
GAA P10253 1/20 0.34
CASP1 P29466 1/20 0.34
BRCA1 P38398 1/20 0.34
CASP7 P55210 1/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16708146 0.83 ALDH1A1 (0.36) PIM1CSNK2A2CSNK2BCSNK2A1CSNK2A3
SCHEMBL16708113 0.83 F2RL3 (0.39) PIM1CSNK2A2CSNK2BCSNK2A1CSNK2A3
SCHEMBL1701238 0.82 PIM1 (0.56) PIM1CSNK2A2CSNK2BCSNK2A1CSNK2A3
SCHEMBL16710637 0.82 ALDH1A1 (0.46) PIM1NPC1RAB9ASTING1LMNA
SCHEMBL16708124 0.76 GSK3B (0.44) PIM1CSNK2A2CSNK2BCSNK2A1CSNK2A3
SCHEMBL16708233 0.76 TAS1R3 (0.53) PIM1GSK3BNPC1RAB9ALMNA
SCHEMBL16708167 0.76 ALDH1A1 (0.40) PIM1CSNK2A2CSNK2BCSNK2A1CSNK2A3
SCHEMBL16708130 0.76 PIM1 (0.37) PIM1CSNK2A2CSNK2BCSNK2A1CSNK2A3
SCHEMBL29609044 0.76 ALDH1A1 (0.40) PIM1CSNK2A2CSNK2BCSNK2A1CSNK2A3
SCHEMBL3721823 0.74 PIM1 (0.68) PIM1NPC1RAB9ALMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9862730-B2 Imidazothiadiazole derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation BRISTOL-MYERS SQUIBB COMPANY (US) 2018-01-09 US disclosed
US-20150133446-A1 IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION UNIVERSITE DE MONTREAL (CA) 2015-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150133446-A1 IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION F2RL3, F2R, F2RL1 PIM1 2132/4885CSNK2A2 1750/4885CSNK2B 1714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.